Injection drug use and hepatitis C: From transmission to treatment

Psychiatric Annals

Volumn 33, Issue 6, 2003, Pages 377-382

  Sylvestre, Diana L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; INTERFERON; METHADONE; PSYCHOTROPIC AGENT; RIBAVIRIN;

ALCOHOL ABUSE; ALCOHOLISM; ANAMNESIS; ARTHRALGIA; BEHAVIOR; CHILL; CLINICAL TRIAL; CORRELATION ANALYSIS; DEPRESSION; DRUG DEPENDENCE; DRUG USE; ENZYME IMMUNOASSAY; EPIDEMIOLOGICAL DATA; FLUID INTAKE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HISTOLOGY; HUMAN; INFECTION; INTRAVENOUS DRUG ABUSE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; MEDICAL EXAMINATION; MENTAL HEALTH CARE; MYALGIA; NEUTROPENIA; PREDICTION; PROSPECTIVE STUDY; RELAPSE; REVIEW; SEROPREVALENCE; THROMBOCYTOPENIA; VIRUS DETECTION; VIRUS LOAD; VIRUS TRANSMISSION; WITHDRAWAL SYNDROME;

EID: 0038819648     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/0048-5713-20030601-07     Document Type: Review

References (22)

1. Centers for Disease Control and Prevention. Vital Health Stat 5. 1999;10.
2. McCarthy JJ, Flynn N. Hepatitis C in methadone maintenance patients: prevalence and public policy implications. J Addict Dis. 2001;20:19-31.
3. Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. Sharing of drag preparation equipment as a risk factor for hepatitis C. Am J Public Health. 2001;91:42-46.
4. Thomas DL, Vlahov D, Solomon L, et al. Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore). 1995;74:212-20.
5. Watters JK, Estilo MJ, Clark GL, Lorvick J. Syringe and needle exchange as HIV/AIDS prevention for injection drug users. JAMA. 1994;271:115-20.
6. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic Non-A, Non-B Hepatitis Study Team. N Engl J Med. 1992;327:1899-905.
7. Consensus Development Panel. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002 - June 10-12, 2002. Hepatology. 2002;36:S3-S15.
8. Schiff ER. The alcoholic patient with hepatitis C virus infection. Am J Med. 1999;107:95S-99S.
9. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors JAMA. 2000;284:450-456.
10. Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Hepatology. 1997;26:485-490.
11. Alter MJ, Kruszon-Moran D, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. New Engl J Med. 1999;341:556-562.
12. Lau DT, Kleiner DE, Ghany MG, Park Y. Schmid P, Hoofnagle JH. 10-year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology. 1998;28:1121-1127.
13. Fried MW, Shiffman ML et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-1082.
14. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus rihavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a ran domised trial. Lancet. 2001;358:958-965.
15. Trask PC, Esper P et al. Psychiatric side effects of interferon therapy: prevalence, pro posed mechanisms and future direction. J Clin Oncol. 200;18:2316-2326.
16. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001;34:188-193.
17. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339:1485-1492.
18. Dalgard O, Bjoro K, Hellum K, et al. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. Eur Addict Res. 2002;8:45-49.
19. Van Thiel DH, Friedlander L, Molloy PJ, Fagiuoli S, Kania RJ, Caraceni P. Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness. Eur J Gastroenterol Hepatol. 1995;7:165-168.
20. Pariante CM, Orru MG, Baita A, Farci MG, Carpiniello B. Treatment with interferonalpha in patients with chronic hepatitis and mood or anxiety disorders. Lancet. 1999;354:131-132.
21. Balkrishnan R. Predictors of medication adherence in the elderly. Clin Ther. 1998;20:764-771.
22. Carney RM, Freedland KE, Eisen SA, Rich MW, Jaffe AS. Major depression and medication adherence in elderly patients with coronary artery disease. Health Psychol. 1995;14:88-90.